205 related articles for article (PubMed ID: 27239089)
1. TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data.
Chen Z; Guo J; Zhang K; Guo Y
Dis Markers; 2016; 2016():4639575. PubMed ID: 27239089
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of p53 alterations in human osteosarcoma: a meta analysis.
Yao D; Cai GH; Chen J; Ling R; Wu SX; Li YP
Int J Clin Exp Pathol; 2014; 7(10):6725-33. PubMed ID: 25400752
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis.
Pakos EE; Kyzas PA; Ioannidis JP
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6208-14. PubMed ID: 15448009
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in TP53 are associated with risk and survival of osteosarcoma in a Chinese population.
Ru JY; Cong Y; Kang WB; Yu L; Guo T; Zhao JN
Int J Clin Exp Pathol; 2015; 8(3):3198-203. PubMed ID: 26045840
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of p53 as a biomarker of survival in patients with osteosarcoma.
Fu HL; Shao L; Wang Q; Jia T; Li M; Yang DP
Tumour Biol; 2013 Dec; 34(6):3817-21. PubMed ID: 24014053
[TBL] [Abstract][Full Text] [Related]
6. Germ-line genetic variation of TP53 in osteosarcoma.
Savage SA; Burdett L; Troisi R; Douglass C; Hoover RN; Chanock SJ;
Pediatr Blood Cancer; 2007 Jul; 49(1):28-33. PubMed ID: 17096406
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.
Wunder JS; Gokgoz N; Parkes R; Bull SB; Eskandarian S; Davis AM; Beauchamp CP; Conrad EU; Grimer RJ; Healey JH; Malkin D; Mangham DC; Rock MJ; Bell RS; Andrulis IL
J Clin Oncol; 2005 Mar; 23(7):1483-90. PubMed ID: 15735124
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
9. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
Tang F; Min L; Seebacher NA; Li X; Zhou Y; Hornicek FJ; Wei Y; Tu C; Duan Z
J Orthop Res; 2019 Mar; 37(3):789-798. PubMed ID: 30667081
[TBL] [Abstract][Full Text] [Related]
10. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
11. Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway.
Saba KH; Difilippo V; Kovac M; Cornmark L; Magnusson L; Nilsson J; van den Bos H; Spierings DC; Bidgoli M; Jonson T; Sumathi VP; Brosjö O; Staaf J; Foijer F; Styring E; Nathrath M; Baumhoer D; Nord KH
J Pathol; 2024 Feb; 262(2):147-160. PubMed ID: 38010733
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of elevated ezrin in patients with osteosarcoma.
Lun DX; Hu YC; Xu ZW; Xu LN; Wang BW
Tumour Biol; 2014 Feb; 35(2):1263-6. PubMed ID: 24014052
[TBL] [Abstract][Full Text] [Related]
13. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
14. Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma.
Das S; Idate R; Regan DP; Fowles JS; Lana SE; Thamm DH; Gustafson DL; Duval DL
Commun Biol; 2021 Oct; 4(1):1178. PubMed ID: 34635775
[TBL] [Abstract][Full Text] [Related]
15. Germline TP53 variants and susceptibility to osteosarcoma.
Mirabello L; Yeager M; Mai PL; Gastier-Foster JM; Gorlick R; Khanna C; Patiño-Garcia A; Sierrasesúmaga L; Lecanda F; Andrulis IL; Wunder JS; Gokgoz N; Barkauskas DA; Zhang X; Vogt A; Jones K; Boland JF; Chanock SJ; Savage SA
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25896519
[TBL] [Abstract][Full Text] [Related]
16. Association between TP53 rs1042522 gene polymorphism and the risk of malignant bone tumors: a meta-analysis.
Huang X; Wu F; Zhang Z; Shao Z
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30833364
[No Abstract] [Full Text] [Related]
17. Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.
Ma X; Le Teuff G; Lacas B; Tsao MS; Graziano S; Pignon JP; Douillard JY; Le Chevalier T; Seymour L; Filipits M; Pirker R; Jänne PA; Shepherd FA; Brambilla E; Soria JC; Hainaut P;
J Thorac Oncol; 2016 Jun; 11(6):850-61. PubMed ID: 26899019
[TBL] [Abstract][Full Text] [Related]
18. COPS3 amplification and clinical outcome in osteosarcoma.
Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL
Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602
[TBL] [Abstract][Full Text] [Related]
19. Association Between TP53 Mutation and Prognosis in Wilms Tumor: A Meta-Analysis.
Lizhi L; Rongdong H; Shaohua H; Yingquan K; Huihuang X; Shan L; Kunbin T; Di X
Fetal Pediatr Pathol; 2021 Dec; 40(6):653-662. PubMed ID: 32066305
[No Abstract] [Full Text] [Related]
20. Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma.
Serra M; Maurici D; Scotlandi K; Barbanti-Brodano G; Manara MC; Benini S; Picci P; Bertoni F; Bacci G; Sottili S; Baldini N
Int J Oncol; 1999 Feb; 14(2):301-7. PubMed ID: 9917506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]